We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

This study is currently recruiting participants.
Verified November 2017 by Dr Tri Juli Edi Tarigan, SpPD-KEMD, Indonesia University
Sponsor:
ClinicalTrials.gov Identifier:
NCT03352674
First Posted: November 24, 2017
Last Update Posted: November 27, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Dr Tri Juli Edi Tarigan, SpPD-KEMD, Indonesia University
  Purpose
This is an open-label randomised multicenter clinical study to compare immunogenicity of the drug products Insulin Glargine (Kalbe Farma) and Lantus (Sanofi -Aventis) in type 2 diabetes mellitus patients

Condition Intervention Phase
Diabetes Mellitus Drug: Insulin Glargine Ezelin Drug: Insulin Glargine Pen Injector [Lantus] Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Open Label Randomized Multicenter Clinical Trial to Compare Immunogenicity of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

Resource links provided by NLM:


Further study details as provided by Dr Tri Juli Edi Tarigan, SpPD-KEMD, Indonesia University:

Primary Outcome Measures:
  • Incidence of immune response [ Time Frame: 6 months ]
    Production of antibodies against insulin /IAA and ZnT8 antibody in investigational drug product and comparator groups


Secondary Outcome Measures:
  • HbA1c [ Time Frame: 6 months ]
    change in HbA1c level after 6 months of therapy compared to baseline value

  • Fasting blood glucose [ Time Frame: 6 months ]
    Change in fasting blood glucose

  • Hypoglycemia [ Time Frame: 6 months ]
    Incidence and severity of hypoglycaemia cases

  • Adverse events [ Time Frame: 6 months ]
    Incidence and severity of adverse events


Estimated Enrollment: 120
Actual Study Start Date: September 2016
Estimated Study Completion Date: June 1, 2018
Estimated Primary Completion Date: June 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Insulin Glargine Ezelin
Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
Drug: Insulin Glargine Ezelin
Insulin Glargine (Ezelin) once daily at individually adjusted dose
Other Name: Ezelin
Active Comparator: Insulin Glargine Lantus
Insulin Glargine Pen Injector [Lantus]
Drug: Insulin Glargine Pen Injector [Lantus]
Insulin Glargine (Lantus) once daily at individually adjusted dose
Other Name: Lantus

Detailed Description:
Previous study has revealed that Insulin Glargine (Kalbe Farma) has similar efficacy with Lantus (Sanofi-Aventis) in controlling blood glucose in type 2 diabetes mellitus patients, but the immunogenicity potential of this product has not been known. Therefore, the present study is aiming to compare immunogenicity of Insulin Glargine (Kalbe Farma) and Lantus (Sanofi-Aventis) in type 2 diabetes mellitus patients in an open-label randomised multicenter clinical study.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women, 18 years old and above
  • Diabetes mellitus type 2 patients who has failed an oral hypoglycemic drug products, insulin-naive, disease duration of at least 6 months, inadequate glycemic control (HbA1c > 7.0 %)
  • BMI ranged from 19 - 35 kg/m2
  • Consent from patients of childbearing potential to use contraception method throughout the study
  • Signed informed consent form

Exclusion Criteria:

  • History of diabetic ketoacidosis more than 2 times in the past 1 year
  • History of pancreatectomy
  • Estimated glomerular filtration rate <30 mL/min
  • Positive ZnT8 Antibody
  • Treatment with glucocorticoids, immunodepressant or cytostatics in 60 days before study.
  • Any malignant disease, including in medical history
  • Drugs and alcohol abuse, including in medical history
  • Hipersensitivity to insulin glargine or any excipient of the drugs from medical history
  • Mental disorders
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03352674


Contacts
Contact: Melva Louisa, PhD melva.louisa@gmail.com
Contact: Adisti Dwijayanti, MD adistimiltiades@gmail.com

Locations
Indonesia
Department of Internal Medicine Cipto Mangunkusumo Hospital, Faculty of Medicine Universitas Indonesia Recruiting
Jakarta Pusat, Jakarta, Indonesia, 10520
Contact: Tri Juli Edi Tarigan, MD       tje_tar@yahoo.com   
Sponsors and Collaborators
Indonesia University
Investigators
Principal Investigator: Tri Juli Edi Tarigan, MD Cipto Mangunkusumo Hospital/Faculty of Medicine Universities Indonesia
  More Information

Publications:

Responsible Party: Dr Tri Juli Edi Tarigan, SpPD-KEMD, Endocrinologist, Principal Investigator, Indonesia University
ClinicalTrials.gov Identifier: NCT03352674     History of Changes
Other Study ID Numbers: IndonesiaU-01
First Submitted: October 14, 2017
First Posted: November 24, 2017
Last Update Posted: November 27, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dr Tri Juli Edi Tarigan, SpPD-KEMD, Indonesia University:
insulin glargine
diabetes mellitus
immunogenicity

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs